18: Autologous peripheral blood stem cell transplant using busulfan, etoposide, high dose Ara-C, and G-CSF priming as conditioning regimen in patients with acute myeloid leukemia in first complete remission

Moscardó, Federico; Mediavilla, Joaquín Díaz; Rubia, Javier de la; Fernández, Pascual; Rayón, Consuelo; Cañigral, Guillermo; Arias, Jesús; Palomera, Luis; Bello, José-Luis; Alcalá, Antonio; Sayas, Ma José; Burgaleta, Carmen; Mateos, M. V.; Amador, Lauro Fabian; Pérez, Montserrat; Fernández, Rosa; García, Javier Moreno; Martín, M.A.; Román, A; Queizán, José Antonio; Fernandez, JM; Sanz, MA

doi:10.1016/j.bbmt.2006.12.021

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we should highlight a considerably lower NRM in patients who received BEA (0.6% at 2 years and 1.5% at 5 years), con rming previous results with this conditioning regimen. 5,7,8 Replacement of the alkylating agents cyclophosphamide and melphalan with more speci c AML drugs, such as the topoisomerase inhibitor etoposide and the DNA polymerase inhibitor cytarabine, could have led to reduced toxicity.…”

Section: Discussionmentioning

confidence: 99%

“…Following encouraging preliminary results, 5,6 another alternative to the classic BUCY regimen, replacing cyclophosphamide with etoposide and high-dose cytarabine (BEA regimen), along with granulocyte colony-stimulating factor (G-CSF) priming, has been increasingly used in patients with AML in CR1. [7][8][9] The promising results reported with BEA prompted us to compare the safety and e cacy of BEA, BUMEL, and BUCY as preparative regimens for ASCT in patients with AML in CR1, registered in the EBMT database.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

Sanz

Labopin

Pabst

et al. 2023

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

Sanz

Labopin

Pabst

et al. 2023

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the EBMT

Labopin

Pabst

Versluis

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction High-dose myeloablative chemotherapy followed by autologous stem cell transplantation (ASCT) is a valid treatment option for patients with acute myeloid leukemia (AML) in first complete remission (CR1). However, information on specific conditioning regimens is scarce. The ALWP showed improved outcomes with busulfan and high-dose melphalan (BUMEL) conditioning compared to busulfan with cyclophosphamide (BUCY) in high-risk patients. The combination of more AML directed drugs using high-dose cytarabine, etoposide and busulfan (BEA) has been the recommended regimen in subsequent PETHEMA studies. Methods In order to analyse the impact of the conditioning regimen we retrospectively compared the outcome of adult patients with AML in CR1 that received an ASCT from 2010 to 2021 with either BEA, BUCY or BUMEL registered in the EBMT database. Results Overall 1560 patients underwent ASCT at a median age of 52 years (range, 18–75). Eight hundred and forty-three (54%) were male. Two hundred and sixty-seven (23%), 815 (70%) and 75 (7%) had favorable-, intermediate- and adverse-risk cytogenetics, respectively (data not reported for 403 patients). FLT3-ITD and NPM1 mutations were present in 177 (23%) and 481 (58%) patients, respectively. Regarding conditioning, 156, 1143 and 261 received BEA, BUCY and BUMEL, respectively. Compared to BUCY and BUMEL, BEA patients were younger (p < 0.001) and less frequently had NPM1 mutations (p = 0.03). Transplant outcomes at 5 years with BEA, BUCY and BUMEL were: cumulative incidence of relapse 41.8%, 46.6% and 51.6%; non-relapse mortality (NRM) 1.5%, 5.2% and 7.3%; probability of leukemia-free survival (LFS) 56.7%, 48.2% and 41.1%; and overall survival (OS) 71.3%, 62.3% and 56%, respectively. In multivariable analysis the BEA regimen showed significant improvement in OS compared to BUCY (hazard ratio [HR] 0.65; 95% CI, 0.42–0.83; p = 0.048) and BUMEL (HR 0.59; 95% CI, 0.37–0.94; p = 0.029). Favorable cytogenetics and younger age were also associated with improved OS. Conclusions High-dose myeloablative combination chemotherapy with BEA offered improved outcomes compared to classical BUCY or BUMEL in patients with AML in CR1 undergoing ASCT.

show abstract

18: Autologous peripheral blood stem cell transplant using busulfan, etoposide, high dose Ara-C, and G-CSF priming as conditioning regimen in patients with acute myeloid leukemia in first complete remission

Cited by 2 publications

References 0 publications

Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the EBMT

Contact Info

Product

Resources

About